Poziotinib

Phase 3Small molecule

Poziotinib is one of 119 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Lung AdenocarcinomaActive, not recruiting

Breast CancerActive, not recruiting

NSCLCSuspended

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Lung AdenocarcinomaPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

NSCLCPhase 3

Suspended

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Poziotinib

Spectrum Pharmaceuticals, Inc

Phase 3

3 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Zolymbus

AbbVie

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Zinecard

CChildren's Oncology Group

Preclinical

2 8

Acupan

YYonsei University

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer3 trials

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Terminated· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 1·NCT03429101·6 enrolled

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 2·NCT02659514·67 enrolled

A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

Completed·SSamsung Medical Center·Phase 2·NCT02544997·5 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Completed·SSeoul National University Hospital·Phase 2·NCT03292250·180 enrolled

Adult1 trial

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 1·NCT04981704·74 enrolled

Lung Adenocarcinoma1 trial

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

Completed·KKorean Association for the Study of Targeted Therapy·Phase 2·NCT02979821·6 enrolled

Advanced NSCLC1 trial

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03066206·93 enrolled

4 more indications

Exon 201 trial

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Terminated· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 2·NCT04044170·5 enrolled

Acute Lymphoblastic Leukemia1 trial

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Terminated· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 2·NCT03744715·7 enrolled

Phase 21 trial

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Terminated· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 2·NCT03318939·648 enrolled

NSCLC1 trial

A Randomized, Phase 3 Study of Poziotinib in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring HER2 Exon 20 Mutations (PINNACLE)

Suspended· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT05378763·268 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Poziotinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Poziotinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Poziotinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Spectrum Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Spectrum Pharmaceuticals, Inc

Poziotinib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer3 trials

Esophageal Squamous Cell Carcinoma1 trial

Adult1 trial

Lung Adenocarcinoma1 trial

Advanced NSCLC1 trial

Exon 201 trial

Acute Lymphoblastic Leukemia1 trial

Phase 21 trial

NSCLC1 trial

References

Drug Info

Quick Facts

Related News